Emmaus Life Sciences Reports Q2 2026 Financial Results

What Happened
Emmaus Life Sciences, Inc. announced on August 14, 2026 that it issued a press release reporting its results of operations and financial condition for the three and six months ended June 30, 2026. The press release is attached to the Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• The 8-K (Item 2.02) discloses results of operations and financial condition for the three- and six-month periods ended June 30, 2026.
• The press release announcing those results was issued on August 14, 2026.
• The press release is included as Exhibit 99.1 to the Form 8-K and is incorporated by reference.
• The Form 8-K also lists the related exhibits under Item 9.01.

Why It Matters
This filing signals that Emmaus has publicly released its quarterly operating and financial information for Q2 2026. Retail investors should read the attached press release (Exhibit 99.1) and related SEC filings to see the detailed figures—such as revenue, net income/loss, cash position and any management commentary—which can affect valuation and near-term trading. Because the Form 8-K itself references the press release rather than presenting full financial tables in-line, consult the exhibit for the complete results.